Industry
Biotechnology
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Loading...
Open
9.55
Mkt cap
1.1B
Volume
734K
High
10.53
P/E Ratio
-5.33
52-wk high
16.63
Low
9.00
Div yield
N/A
52-wk low
6.88
Portfolio Pulse from Benzinga Newsdesk
June 12, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:42 am
Portfolio Pulse from Vandana Singh
June 05, 2024 | 7:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 8:22 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 1:49 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 10:56 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 1:20 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:28 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.